Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Morphosys Ag ADR
(NQ:
MOR
)
18.96
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Morphosys Ag ADR
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI on Behalf of Shareholders
July 17, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
3 Global Stocks to Buy to Escape the Volatility on Wall Street
July 16, 2024
Discover three top global stocks as a smart hedge against Wall Street volatility, offering diversification and resilience in uncertain times.
Via
InvestorPlace
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
July 12, 2024
From
MorphoSys AG
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DM, SHCR, MOR, ALE on Behalf of Shareholders
July 08, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
MorphoSys: Q4 Earnings Insights
March 13, 2024
Via
Benzinga
Earnings Outlook For MorphoSys
March 12, 2024
Via
Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, MOR, BEST, MGOL on Behalf of Shareholders
June 29, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders
June 20, 2024
From
Halper Sadeh LLC
Via
Business Wire
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
June 20, 2024
From
MorphoSys AG
Via
Business Wire
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
June 19, 2024
Via
ACCESSWIRE
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
March 07, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Monday's After-Market Session
May 27, 2024
Via
Benzinga
MOR Stock Earnings: MorphoSys Misses EPS, Misses Revenue for Q1 2024
April 30, 2024
MOR stock results show that MorphoSys missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
MorphoSys AG Reports First Quarter 2024 Financial Results
April 29, 2024
From
MorphoSys AG
Via
Business Wire
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
April 29, 2024
MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds...
Via
Benzinga
Exposures
Product Safety
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
April 24, 2024
Via
ACCESSWIRE
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
April 23, 2024
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow.
Via
Benzinga
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
April 11, 2024
From
MorphoSys AG
Via
Business Wire
MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
April 11, 2024
Via
ACCESSWIRE
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
March 21, 2024
Via
ACCESSWIRE
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 13, 2024
From
MorphoSys AG
Via
Business Wire
Earnings Scheduled For March 13, 2024
March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Via
Benzinga
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
March 09, 2024
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the...
Via
Talk Markets
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
March 07, 2024
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth.
Via
InvestorPlace
Exit Now! 3 Biotech Stocks to Sell in February 2024
February 21, 2024
These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability.
Via
InvestorPlace
Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B
February 06, 2024
Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat.
Via
Benzinga
Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion
February 05, 2024
Novartis will add to its cancer treatment pipeline with via the German biotech.
Via
Investor's Business Daily
Why Is MorphoSys (MOR) Stock Up 50% Today?
February 05, 2024
News of a potential takeout bid for any company usually leads to a big surge. That's what investors are seeing today with MOR stock.
Via
InvestorPlace
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 05, 2024
Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS...
Via
Benzinga
MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer
February 05, 2024
Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.